ASOs have proven effective against preclinical models of ALS characterized by SOD1 mutations and C9orf72 repeat expansions; clinical studies utilizing intrathecal administration of ASOs targeting these genes are currently ongoing. This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.